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Background and objectives: Despite advances, inappropriate analgesic treatment for burn 
patients is still seen. The objective of this review was to collect data on pain management in 
burn patients.
Content: We reviewed the mechanisms of pain, burn patient assessment, as well as pharmacological 
and non-pharmacological treatment.
Conclusion: Pain management in burn patients is still a challenge for the multidisciplinary 
team. Frequent and continuous evaluation of the patient’s response is very important due to 
the various stages that the hospitalized burn patient goes through, as well as a combination 
therapy with analgesic and non-pharmacological measures. Understanding the complexity of the 
pathophysiological, psychological, and biochemical changes a burn patient presents is the ﬁ rst 
step to achieve success in analgesic management.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Despite signiﬁ cant recent advances regarding treatment for 
burn victims, the inappropriate analgesic management is 
still seen 1. This is due to both the complex nature of pain 
presented by these patients and insufﬁ cient training of the 
professionals involved 2-4.
The inadequate control of pain may diminish trust within 
the medical team, which may negatively affect the treatment 
outcome 5. Moreover, it may contribute to the development 
of chronic pain, paresthesia, and dysesthesia 6-11. There is 
an association between insufﬁ cient pain relief and the onset 
of some psychiatric disorders, such as depression and post-
traumatic stress disorder 12.
A successful treatment requires careful assessment of 
its nature, understanding the different types and patterns 
of pain and knowing the best treatment. A good initial as-
sessment serves as a baseline to evaluate the results of 
subsequent interventions 13.
A multidisciplinary approach to these patients is 
critical, due to the complexity of factors involved in pain. 
During hospitalization, analgesia requirements vary be-
cause of the numerous procedures that patients undergo 
as well as their evolving condition. This makes it difﬁ cult 
to predict the amount of analgesic to be administered at 
a given time.
This review aims to present the main forms of pharma-
cological and non-pharmacological management of pain 
available in the literature.
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the effect of drugs with high protein binding is difﬁ cult to 
control 24. One should also be cautious with increased total 
body water commonly seen during treatment.
Opioids
Among the most commonly used drugs, opioids play a key 
role in pain management in burn patients. The variety of 
options available in the market allows good ﬂ exibility regard-
ing potency, route of administration, and duration of action 
tailored to each patient. Its adverse effects are well-known, 
particularly itching, respiratory depression, and nausea. Due 
to the risk of tolerance or opioid-induced hyperalgesia, its 
use should always be incorporated into a multimodal treat-
ment approach 25.
The pain at rest (background pain) present in burn pa-
tients is moderate and should be treated more appropriately 
with moderate potency drugs, whose plasma concentration 
remains relatively constant throughout the day. The most 
common examples are: intravenous opioid infusion, with 
or without patient-controlled analgesia, long-term opioids 
(methadone) administered orally, or prolonged enteral ab-
sorption opioids (controlled-release morphine or oxycodone). 
Tramadol and opioids also promote a beneﬁ cial effect in neu-
ropathic pain 26,27. There is no evidence in literature regarding 
the superiority of a particular opioid for neuropathic pain 
treatment 24. Remifentanil, an opioid with ultra rapid onset 
of action and plasma metabolism, is an important option for 
analgesia during procedures when delivered by continuous 
infusion. Fentanyl and alfentanil may also be used, with the 
advantage of promoting residual analgesia.
Anti-inﬂ ammatory drugs, paracetamol and dipyrone
These medications may reduce the amount of opioid needed 
by up to 20-30%. %. Nonsteroidal anti-inﬂ ammatory drugs 
(NSAIDs) may also reduce the adverse effects of opioids signif-
icantly 28. The most appropriate drugs for patients with burns 
are paracetamol, dipyrone, and selective cyclooxygenase-2 
inhibitors. Although these drugs are weak when used alone, 
they act synergistically with opioids 29. Due to the inhibition 
of platelet aggregation, the use of NSAIDs should be avoided 
in situations in which risk of bleeding is a concern (such as 
severe burn) 30. Its use also requires caution in patients with 
cardiovascular and gastrointestinal diseases 31.
Anticonvulsants
Gabapentin and pregabalin are often used for treating neuro-
pathic pain in burn patients. Directly, these drugs diminish the 
central sensitization of pain by binding to calcium channels; 
indirectly, they inhibit presynaptic N-methyl-D-aspartate 
(NMDA) receptors 32. In a small study of burn patients, pain 
intensity and opioid consumption were signiﬁ cantly reduced 
in patients taking gabapentin. Between 3 to 24 days after 
the accident, patients received 2,400 mg of it, divided into 
three doses 33. In another study, pregabalin was evaluated and 
well-tolerated, signiﬁ cantly reducing several components of 
neuropathic pain in burn patients. Additionally, there were 
fewer pain complaints during procedures 34.
Mechanisms of pain
The pain soon after the burn is due to direct stimulation 
and injury of the nociceptors present in the epidermis and 
dermis, which leads to the transmission of nerve impulses 
by A-delta and C ﬁ bers to the spinal cord dorsal horn. The 
impulse magnitude is modulated by both the peripheral 
stimuli and descending inﬂ uences from the brain 14.
The inﬂ ammatory response is initiated minutes after in-
jury and leads to the release of numerous chemical irritants 
that for several days sensitize and stimulate the nocicep-
tors at the site. The site remains painful and sensitive to 
mechanical and thermal stimuli, with primary hyperalgesia. 
The change in sensitivity to mechanical stimuli seen in the 
injury adjacent tissues is referred to as secondary hyper-
algesia. The quality of pain changes, as the inﬂ ammatory 
response subsides. Pain intensity varies, but it is typically 
at its maximum in places of skin loss and tissue donor areas. 
In case of severe burns, the initial destruction of nerve end-
ings leads to local insensitivity to pain. In these areas, there 
may be a disorderly regeneration of nerve tissue, which will 
predispose to neuropathic pain. It is estimated that up to 
52% of burn patients have chronic pain 15.
Evaluation
It is extremely important to evaluate constantly the burn 
victim for pain in order to guide the analgesic management 
and response to drug 7. Characteristics, such as pain location, 
pain improvement or worsening, and type and intensity of 
pain are essential for management.
Pain intensity in this group of patients is usually assessed 
using a numerical scale (0-10). However, the visual analogue 
scale, verbal descriptive scale, and faces and colors scales 
are used 16. There are also behavioral observational scales 
validated for use in patients who are unable to express 
themselves effectively. The Abbey pain scale (for elderly with 
cognitive disorders) 17 and FLACC score (for young children) 18 
are reported.
Four patterns of pain have been observed in burn pa-
tients. There may be constant pain at rest and in motion 
(background pain), aggravated by episodes of intense and 
sudden pain (breakthrough pain), pain during procedures 16, 
and pain in the postoperative period.
Pharmacological treatment
Drug administration is the primary and most effective way of 
treating pain in burn patients because of its nature and inten-
sity 19. As mentioned previously, the inadequate management 
of analgesia is still very common and it is extremely important 
to continually reassess the effectiveness of therapy, as well 
as the use of more aggressive methods 20-23.
Some changes in drug pharmacokinetics are seen in burn 
patients. During the initial phase, when an inﬂ ammatory 
response develops, there is decreased blood ﬂ ow to the 
organs, with a consequent drug clearance decrease. After 
this phase, there is an overall increase of metabolism with a 
subsequent clearance increase. In burn injuries with a body 
surface area greater than 20%, there is a widespread capil-
lary leakage, with loss of interstitial proteins. Therefore, 
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Antidepressants
Antidepressants are effective drugs and therefore play an 
important role in the concept of multimodal treatment of 
pain associated with burns 35. Amitriptyline, used in low 
doses, has an established role in the management of neuro-
pathic pain. It acts by activating the descending inhibitory 
pathways in the spinal cord. The required dose is usually 
not more than 75 mg per day. Selective serotonin reuptake 
inhibitors may also be used in case of intolerance to side 
effects of tricyclics.
The analgesic effect of antidepressants usually occurs 
within days or weeks. There are no studies regarding the 
analgesic effect and time to start analgesic therapy in burn 
patients 24.
Ketamine
Ketamine is a non-competitive antagonist of NMDA recep-
tors and may be used for conscious sedation during dressing 
changes in burn patients 36. It induces a state of dissociative 
anesthesia with intravenous doses of 1 mg.kg-1. As an ad-
vantage, it maintains the airway reﬂ exes, blood pressure, 
and heart rate by indirect release of norepinephrine. The 
occurrence of hallucinations, a signiﬁ cant adverse effect, 
may be attenuated by concomitant administration of ben-
zodiazepines or propofol 37,38. In a meta-analysis of ketamine 
at low doses and postoperative consumption of opioids, the 
authors concluded that there is a reduction of up to one-third 
in total dose administered. Furthermore, ketamine was ef-
fective as rescue medication in case of pain less responsive 
to opioids 39. Ketamine appears to promote some action in 
reducing hyperalgesia 59.
Benzodiazepines
Because anxiety disorders may exacerbate pain complaints, 
the use of anxiolytics associated with analgesic drugs is a 
common practice in many centers 40,41. Fear and tension 
cause decreased pain tolerance 42. The burn patients who 
beneﬁ ted most from therapy with benzodiazepines were 
those extremely anxious and with severe pain 43. When there 
is need for rapid onset of action, midazolam may be used. 
Lorazepam is more suitable than diazepam for this group of 
patients because of the decreased hepatic metabolism often 
present, which may prolong the half-life of the latter 44.
Lidocaine
Therapy with intravenous lidocaine was effective in reduc-
ing neuropathic pain scores, mainly associated with nerve 
injury 45. A clinical study, however, showed only a small dif-
ference in pain scores, requiring opioid maintenance doses 
during burn patients’ dressing changes 46.
Alpha-2 agonist
Alpha-2 agonists have interesting properties that facilitate 
their use in analgesic management of burn patients. Besides 
stimulating the descending inhibitory pain pathways, they 
have sedative and antihypertensive effects. Clonidine may 
be used safely in analgesic management of child burn vic-
tims 47,48. In some burn centers, it is routinely prescribed for 
children and adults. Dexmedetomidine has a shorter duration 
of action than clonidine and its action is more selective for 
alpha-2 receptors. One study reported positive results in the 
association between ketamine and dexmedetomidine com-
pared to ketamine alone or in combination with midazolam 
during dressing changes in burn patients 49.
Non-pharmacological treatment
Non-pharmacological therapy is an important measure com-
plementary to medication to manage pain and anxiety in burn 
patients. It should be initiated as early as possible in order to 
prevent the development of anxiety, which can perpetuate 
the cycle of pain 16. The approach should be multidisciplinary, 
involving psychologists, psychotherapists, physiotherapists 
and pain specialists.
Psychology techniques such as relaxation, distraction, 
and cognitive-behavioral therapy, are beneﬁ cial for relieving 
anxiety and pain during rehabilitation 50-52.
Hypnosis is an altered state of consciousness charac-
terized by increased receptivity to suggestion, ability to 
change perceptions and sensations, and increased capacity 
for dissociation 53. It has been used in pain management 
in burn patients during procedures and to control anxiety. 
Neurophysiological studies support this therapy 54.
Another approach used successfully is virtual reality. It 
consists of a technology that isolates the patient from the 
real world, letting his vision only in contact with a three-
dimensional virtual environment. In the context of burn 
patients, this virtual world is called SnowWorld, specially cre-
ated to counter sensations most commonly caused by a burn 
injury. In some studies, virtual reality used as a technique of 
distraction during procedures was effective in reducing the 
intensity of pain in burn patients 55,56.
Conclusion
Pain management in burn patients is still a challenge for the 
multidisciplinary team. Frequent and continuous evaluation 
of the patient’s response is very important, due to the vari-
ous stages that the hospitalized burn patient goes through, 
as well as a combination therapy with analgesic and non-
pharmacological measures. Understanding the complexity 
of the pathophysiological, psychological, and biochemical 
changes presented by a burn patient is the ﬁ rst step to 
achieve success in analgesic management.
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